Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey-Reference-Cited by-同舟云学术

Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey

Published:2011-10 Issue:9798 Volume:378 Page:1231-1243
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Yusuf Salim,Islam Shofiqul,Chow Clara K,Rangarajan Sumathy,Dagenais Gilles,Diaz Rafael,Gupta Rajeev,Kelishadi Roya,Iqbal Romaina,Avezum Alvaro,Kruger Annamarie,Kutty Raman,Lanas Fernando,Lisheng Liu,Wei Li,Lopez-Jaramillo Patricio,Oguz Aytekin,Rahman Omar,Swidan Hany,Yusoff Khalid,Zatonski Witold,Rosengren Annika,Teo Koon K

Publisher

Elsevier BV

Subject

General Medicine

Reference34 articles.

1. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization;Yusuf;Circulation,2001

2. Beta blockade during and after myocardial infarction: an overview of the randomized trials;Yusuf;Prog Cardiovasc Dis,1985

3. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients;N Engl J Med,2000

4. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials;Dagenais;Lancet,2006

5. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials;Lancet,2010

Cited by 814 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rationale, Design and Baseline Characteristics of a Randomized Controlled Trial of a Cardiovascular Quality Improvement Strategy in India: The C-QIP Trial;American Heart Journal;2024-10

2. Variation in secondary prevention of coronary heart disease: the INTERASPIRE study;European Heart Journal;2024-08-30

3. Use of Cardiovascular Disease Secondary Prevention Medications in Four Middle East Countries in a Community Setting;Global Heart;2024-08-26

4. Adherence to optimal medical therapy and control of cardiovascular risk factors in patients after ST elevation myocardial infarction in Mexico;Frontiers in Cardiovascular Medicine;2024-07-23

5. Comparative analysis of atherosclerotic cardiovascular disease burden between ages 20–54 and over 55 years: insights from the Global Burden of Disease Study 2019;BMC Medicine;2024-07-19